Genmab — November 2018
-
-
God morgen.

-
-
"Ud over godkendelsen i første linje havde investorer og analytikere fokus på det let skuffende salg i tredje kvartal, som blev begrundet med den af Genmab uventede prisjustering af Darzalex i Europa fra partneren Janssen.
Ifølge Genmab har partneren bekræftet, at det var en engangshændelse, og der ikke er planlagt yderligere prisnedsættelser foreløbigt".
-
Spørgsmål til Q&A er meget velkommen.

-
-
Fin start.
-
-
Same shit...Anonyme har fast greb om kursen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind